{"url_path":"/sec/cgtx/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1455365/0001104659-26-057545-index.html","accession_number":"0001104659-26-057545","cik":"0001455365","ticker":"CGTX","issuer_name":"COGNITION THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1455365/0001104659-26-057545-index.html","primary_entity_key":"0001455365","primary_entity_name":"COGNITION THERAPEUTICS INC"},"word_count":118,"has_tables":true,"body_markdown":"Item 1. Legal Proceedings\n\nWe are not aware of any pending legal actions that would, if determined adversely to us, have a material adverse effect on our business and operations.\n\nWe may, from time to time, become involved in disputes and proceedings arising in the ordinary course of business. In addition, as a public company, we are also potentially susceptible to litigation, such as claims asserting violations of securities laws. Any such claims, with or without merit, if not resolved, could be time-consuming and result in costly litigation. There can be no assurance that an adverse result in any future proceeding would not have a potentially material adverse effect on our business, results of operations, and financial condition."}